In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Battle For OGS

Executive Summary

Celltech's hostile bid for OGS may have scuppered the company's cosy merger plans with CAT. But OGS isn't giving in without a fight. And Celltech's offer may even prove beneficial to OGS shareholders, bumping up the firm's price-tag for CAT--or another suitor.

You may also be interested in...



Glycoform Ltd.

Glycoform Ltd. aims to leverage the pioneering glyco-chemistry research of its Oxford University founders to develop targeted drug delivery systems and to improve the safety and efficacy of protein therapeutics, including monoclonal antibodies, by taking advantage of the way specific oligosaccharides, or sugar motifs, can affect the properties of the proteins they decorate.

Biotechs Beware: Royalty Offset Clauses Can Seriously Damage Your Health

Cambridge Antibody's royalty dispute with partner Abbott over potential blockbuster Humira sends a sobering message to biotechs: beware poorly-constructed royalty offset clauses. The argument won't help Abbott's partnering image, either.

CAT Fight with Abbott: The Calculus of Royalty Offsets and Partnering Reputation

The fight between Abbott Laboratories and Cambridge Antibody Technology over two partly overlapping royalty-giveback clauses in their contract on Humira has implications far beyond the money--which itself is not inconsiderable. Abbott could theoretically save itself some $60 million in royalty fees, but it could also win itself a name for playing hardball with its partners, even in the event of a major drug development success.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel